The American Urological Association (AUA) and the Urology Care Foundation recognize that lutinizing hormone-releasing hormone (LH-RH) analog therapy for prostate cancer provides a biochemical castration without performing a bilateral orchiectomy. Furthermore, there may be be psychological benefit regarding body image in not removing the testicles. LH-RH analog therapy may be indicated in a number of situations including, but not limited to the following: as an adjunct to planned curative radiation therapy, a rising PSA after radiation therapy, a rising prostate-specific antigen (PSA) after radical prostatectomy, a rising PSA after cryotherapy, metastatic prostate cancer (with or without symptoms), for local symptoms from prostate cancer (obstruction, bleeding, pain) and patients who are too ill to undergo more aggressive forms of therapy.
A rising PSA in a patient who has been on LH-RH analog therapy does not eliminate the benefit of the drug.
Board of Directors, June 2000
Board of Directors, February 2005 (Revised)
Board of Directors, October 2008 (Revised)
Board of Directors, October 2013 (Revised)